Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.

Richard K Burt Xiaoqiang Han Kathleen Quigley Irene B Helenowski Roumen Balabanov

Published in: Journal of neurology (2021)

In patients with RRMS, autologous non-myeloablative HSCT is an effective one-time therapy, while HSCT appears of less benefit for newly diagnosed SPMS.

Keyphrases

newly diagnosed
cell therapy
bone marrow
hematopoietic stem cell
platelet rich plasma
stem cell transplantation
acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
stem cells
mesenchymal stem cells
low dose